Dual cyclin‐dependent kinase 4/6 inhibition by PD‐0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Aberrant activation of the cyclin D1‐cyclin‐dependent kinase 4/6 (CDK4/6)‐Rb signalling pathway is common in oesophageal squamous cell carcinoma (ESCC). PD‐0332991, a highly specific inhibitor of CDK4/6, has potent antitumour activity against many types of cancer. The purpose of this study was to examine the in vitro and in vivo antineoplastic effect of PD‐0332991 against the growth and metastasis of ESCC cells. Experimental Approach: Cell viability and any synergy between PD‐0332991 and 5‐fluorouracil or cisplatin were measured by MTS assay and CalcuSyn software respectively. Cell migration and invasion were detected by wound healing and transwell assays. Apoptosis was evaluated by flow cytometry after staining annexin V‐FITC/PI. Cellular senescence was assessed by measuring SA‐β‐gal activity. Nude mouse xenograft models of ESCC were employed to determine the in vivo activity of PD‐0332991 against tumour growth and lung metastasis. Key Results: PD‐0332991 inhibited cellular growth and induced mitochondrial‐dependent apoptosis in ESCC cells. PD‐0332991 also suppressed migration, invasion and the expression of MMP‐2 in ESCC cells. Furthermore, PD‐0332991 treatment caused cell senescence in a FOXM1‐dependent manner. In addition, there was synergy between PD‐0332991 and cisplatin or 5‐fluorouracil. Importantly, the xenografted tumour experiments demonstrated that PD‐0332991 potently inhibits ESCC cell growth and lung metastasis. Conclusions and Implications: PD‐0332991 can elicit a strong antitumour activity against ESCC growth and metastasis and may be a promising candidate drug for the treatment of patients with ESCC. Our results warrant a clinical trial to further evaluate the efficacy of PD‐0332991 in ESCC patients, even those with metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 2×
“The synergistic effect was estimated using the medianeffect method of Chou and Talalay.”
MethodCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 2×
“suppressing phosphorylation of Rb tumour suppressor protein (Malumbres and Barbacid, 2009).”
BackgroundAnimal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · cited 2×
“Of note, PD-0332991 has recently been approved by the FDA for use, in combination with letrozole, as a first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (Dhillon, 2015; Finn et al., 2015; 2016) or in combination with fulvestrant for the treatment of women with hormone receptor-…”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · cited 1×
“Rb phosphorylation facilitates the release of Rb from E2F transcription factor, enabling E2F to transcribe the genes that are required for cell cycle progression from the G1 to the S phase and ultimately for cellular proliferation (Musgrove et al., 2011; Reynolds et al., 2014).”
BackgroundMcGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 4×
“PD-0332991 is an orally active, water soluble cellpermeable pyridopyrimidine, that potently inhibits the activity of recombinant CDK4 and CDK6 (IC50 = 11–15 nM) by competing with ATP-binding sites (Fry et al., 2004).”
BackgroundInfluentialMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · cited 4×
“, 2004), whereas CDK4/CDK6 double-knockout embryos die during the late stages of embryonic development due to severe anaemia (Malumbres et al., 2004).”
BackgroundResultInfluential
Cited by
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Esophageal carcinoma: Towards targeted therapies
Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J. (2020) · Cellular Oncology · doi:10.1007/s13402-019-00488-2 · Cited by 158
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
Wang, T.-H., Chen, C.-C., Leu, Y.-L., Lee, Y.-S., Lian, J.-H., Hsieh, H.-L., & Chen, C.-Y. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.12.009 · Cited by 49
Metadata
- Authors
- Chen, L., & Pan, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-06-18
- Volume
- 174
- Issue
- 15
- Pages
- 2427-2443
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2684613524
- Cited by
- 60
- References
- 17
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.